Co-Founder And Ceo
CurrentAt Flomics we're developing a multi-purpose liquid biopsy for the early detection of complex diseases. By combining Next-generation sequencing technologies with data analysis with machine learning we monitor highly informative cell-free RNA molecules that are associated with disease-states to provide a fast, accurate and non-invasive diagnosis opportunity. Currently we are developing our first test s to enable early detection of 5 types of cancer: colon, lung, breast, pancreas and prostate. We are also actively looking for opportunities to expand our porfolio.We also offer a complete range of services of end-to-end genomics solutions to our clients and collaborator.s We can help with individual plasma, saliva or any other body fluid sequencing samples, data analysis, patient screening or large biomarker discover projects.www.flomics.com